Evidence map›Paper›PMID 40521912›Full record

ArticleBasic & clinical pharmacology & toxicology2025

'This Is My Decision': A Qualitative Study of Individuals' Perspectives on Use of Semaglutide for Weight Loss.

Trine Graabæk, Nini Thi Nguyen, Malene Svoldgaard Sørensen, Carina Lundby

Abstract read
In one paragraph

Article in Basic & clinical pharmacology & toxicology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Hunger pain and its reduction; qualitative insight from people with schizophrenia on semaglutide.International journal of qualitative studies on health and well-being · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Trine GraabækHospital Pharmacy Funen, Odense University Hospital, Odense, Denmark.ORCID https://orcid.org/0000-0001-6848-3107
Nini Thi NguyenClinical Institute, University of Southern Denmark, Odense, Denmark.ORCID https://orcid.org/0009-0000-8852-7584
Malene Svoldgaard SørensenHospital Pharmacy Funen, Odense University Hospital, Odense, Denmark.ORCID https://orcid.org/0009-0007-7331-2135
Carina LundbyHospital Pharmacy Funen, Odense University Hospital, Odense, Denmark.ORCID https://orcid.org/0000-0002-2121-6252

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Individuals using semaglutide for weight loss constitute a new, sizeable patient group, yet limited qualitative research of this group exists. Therefore, we explored their perspectives, including motivation for treatment, attitudes towards the medication and experiences with its use. Semistructured interviews with seven individuals (five women, average age 50 years, average treatment duration 9 months) were conducted, audio-recorded, transcribed verbatim and analysed using systematic text condensation. We identified three themes: 'I have absolutely run out of options', 'I am lucky to have a cooperative doctor' and 'It's the feeling of being normal'. Using semaglutide for weight loss was considered a life-changing event, as most respondents were concerned about declining physical health due to overweight. Most showed strong autonomy in managing their treatment, including delaying dose increases, reducing the dose or taking individual doses by 'counting clicks'. Our data suggest a need for more support from healthcare professionals to guide individuals using semaglutide for weight loss, particularly in dosing, monitoring and managing side effects, with an emphasis on individualized and holistic care. Further research on individuals' perspectives related to weight loss and semaglutide use is needed to maintain and improve individuals' quality of life. SUMMARY: More people are using semaglutide to lose weight, but we still know little about their experiences. To learn more, we interviewed seven users. Many saw the treatment as life-changing, having struggled with overweight and concerns about their health. It was important to them to manage the dose themselves. Some delayed increasing the dose or took less than recommended by 'counting clicks'. Our findings show that people using semaglutide for weight loss need more support from healthcare professionals-especially with dosing, side effects and personal guidance. More research is needed to better support these users and improve their quality of life.

Indexed as

Anti-Obesity AgentsGlucagon-Like PeptidesWeight LossAdultAgedDecision MakingFemaleGlucagon-Like Peptide 1HumansMaleMiddle AgedMotivationOverweightQualitative ResearchSemaglutideAnti-Obesity AgentsGlucagon-Like Peptide 1Glucagon-Like PeptidesSemaglutideattitudesinterviewoverweightSemaglutideweight loss

Identifiers

PMID40521912
PMCPMC12168653

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.